BRIEF published on 04/16/2024 at 13:05, 1 year 7 months ago CureVac et MD Anderson collaborent sur des vaccins innovants contre le cancer Technologie ARNm CureVac MD Anderson Vaccins Contre Le Cancer Collaboration Biopharmaceutique
PRESS RELEASE published on 04/16/2024 at 13:00, 1 year 7 months ago CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines CureVac and MD Anderson announce strategic collaboration to develop mRNA-based cancer vaccines, leveraging respective expertise to address unmet medical needs in hematological and solid tumors Clinical Research Collaboration CureVac MD Anderson MRNA-based Cancer Vaccines
BRIEF published on 04/04/2024 at 13:05, 1 year 8 months ago CureVac Reports Positive Phase 2 Results for Influenza Vaccine in Collaboration with GSK GSK MRNA Technology CureVac Influenza Vaccine Phase 2 Trial
BRIEF published on 04/04/2024 at 13:05, 1 year 8 months ago CureVac annonce des résultats positifs de phase 2 pour son vaccin contre la grippe en collaboration avec GSK GSK Technologie ARNm CureVac Vaccin Contre La Grippe Essai De Phase 2
PRESS RELEASE published on 04/04/2024 at 13:00, 1 year 8 months ago CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK CureVac announces positive Phase 2 interim results for seasonal influenza vaccine in collaboration with GSK, showing strong antibody titers and safety profile GSK CureVac Phase 2 Seasonal Influenza Vaccine MRNA
PRESS RELEASE published on 11/01/2023 at 13:00, 2 years 1 month ago CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
PRESS RELEASE published on 09/28/2023 at 13:00, 2 years 2 months ago CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
PRESS RELEASE published on 09/12/2023 at 13:15, 2 years 2 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 09/12/2023 at 13:00, 2 years 2 months ago CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
PRESS RELEASE published on 08/17/2023 at 13:00, 2 years 3 months ago CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Published on 12/05/2025 at 02:35, 11 hours 24 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 59 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 54 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 59 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:45, 14 minutes ago BingX Introduces Recurring Buy to Help Users Ride Out Crypto Market Swings
Published on 12/05/2025 at 13:00, 59 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 59 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 54 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 59 minutes ago CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 08:45, 5 hours 14 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 5 hours 14 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 5 hours 17 minutes ago ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 19 hours 44 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 19 hours 59 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
